Not just diabetes, even chronic bowel inflammation can be treated effectively by injecting insulin into the rectum.
In a new study between departments at the University of Copenhagen and Roskilde University, researchers examined the effect of the treatment in a series of tests on mice with chronic colitis of the type Colitis Ulcerosa, among others.
The cause of these bowel disorders is unknown, but they cause patients great discomfort and can involve bloody diarrhea, anaemia, stomach ache, and weight loss.
Co-inventor of the treatment, Jørgen Olsen said, "Our new treatment with insulin on mice shows great potential against chronic bowel inflammation in humans like Colitis Ulcerosa, which causes a lot of people great discomfort. Existing treatments attack the bowel's immune system, dampening it; instead, our method strengthens the bowel cells' own defence. It appears to work equally well, and it can probably be used in combination with existing treatments."
The researchers have studied the effect of insulin treatment in various ways. First, they have shown that the amount of inflammation, expressed as the level of the marker Cox2, drops by 50 per cent compared to the saltwater control treatment.
Second, the researchers have measured the body weight of the mice - we know that people suffering from colitis typically lose a lot of weight because they do not eat much. As this marker is relatively crude, some studies of the existing treatment have shown no effect at all.
The insulin works because it activates a gene inside the bowel cells, which, according to other studies, has an antioxidant effect and thus may be able to protect the bowel cells from inflammation. This makes the new treatment different from existing medication, which instead of strengthening the bowel's defence weakens the immune system's attack on the bowel. And therefore the researchers hope the new treatment can be combined with the existing.
The full findings are present in the Journal of Crohn's and Colitis.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
